Long-Term Results of Blood and Marrow Transplantation for Hodgkin’s LymphomaGörgün Akpek, Richard J. Jones, Richard F. Ambinder et al.|Journal of Clinical Oncology|2001Cited by 163
Phase <scp>I</scp>/<scp>II</scp> trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJames R. Berenson, Debra Mayo, Stephen J. Noga et al.|British Journal of Haematology|2012Cited by 53
A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myelomaJames R. Berenson, Robert Vescio, James Hilger et al.|Annals of Hematology|2013Cited by 36
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to IxazomibSudhir Manda, Robert M. Rifkin, Habte Yimer et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 16
A phase I/II trial of melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM).Ori Yellin, Robert Vescio, James R. Berenson et al.|Journal of Clinical Oncology|2012Cited by 6